Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy

H. Joachim Deeg, Margaret O'Donnell, Jakub Tolar, Rajni Agarwal, Richard E. Harris, Stephen A. Feig, Mary C. Territo, Robert H. Collins, Peter A. McSweeney, Edward A. Copelan, Shakila P. Khan, Ann Woolfrey, Barry Storer

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

In 87 patients with aplastic anemia who failed to respond to immunosuppressive treatment, we determined the minimal dose of total body irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclophosphamide (CY, 50 mg/kg x 4) to achieve engraftment of unrelated donor marrow. TBI was started at 3 x 200 cGy, to be escalated or deescalated in steps of 200 cGy depending on graft failure or toxicity. Patients were aged 1.3 to 53.5 years (median, 18.6 years). The interval from diagnosis to transplantation was 3 to 328 months (median, 14.6 months). Donors were HLA-A, -B, -C, -DR, and -DQ identical for 62 patients, and nonidentical for 1 to 3 HLA loci at the antigen or allele level for 25. The dose-limiting toxicity was diffuse pulmonary injury. The optimum TBI dose was 1 x 200 cGy. Nine patients did not tolerate ATG and were prepared with CY + TBI. Graft failure occurred in 5% of patients. With a median follow-up of 7 years, 38 (61%) of 62 HLA-identical, and 10 (40%) of 25 HLA-nonidentical transplant recipients are surviving. The highest survival rate with HLA-identical transplants was observed at 200 cGy TBI. Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions.

Original languageEnglish (US)
Pages (from-to)1485-1491
Number of pages7
JournalBlood
Volume108
Issue number5
DOIs
StatePublished - Sep 1 2006

Fingerprint

Transplantation Conditioning
Unrelated Donors
Aplastic Anemia
Whole-Body Irradiation
Immunosuppressive Agents
Bone Marrow
Irradiation
Transplants
Dosimetry
Grafts
Toxicity
Therapeutics
HLA-A Antigens
Antilymphocyte Serum
HLA-B Antigens
Lung Injury
Cyclophosphamide
Survival Rate
Transplantation
Alleles

ASJC Scopus subject areas

  • Hematology

Cite this

Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. / Deeg, H. Joachim; O'Donnell, Margaret; Tolar, Jakub; Agarwal, Rajni; Harris, Richard E.; Feig, Stephen A.; Territo, Mary C.; Collins, Robert H.; McSweeney, Peter A.; Copelan, Edward A.; Khan, Shakila P.; Woolfrey, Ann; Storer, Barry.

In: Blood, Vol. 108, No. 5, 01.09.2006, p. 1485-1491.

Research output: Contribution to journalArticle

Deeg, HJ, O'Donnell, M, Tolar, J, Agarwal, R, Harris, RE, Feig, SA, Territo, MC, Collins, RH, McSweeney, PA, Copelan, EA, Khan, SP, Woolfrey, A & Storer, B 2006, 'Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy', Blood, vol. 108, no. 5, pp. 1485-1491. https://doi.org/10.1182/blood-2006-03-005041
Deeg, H. Joachim ; O'Donnell, Margaret ; Tolar, Jakub ; Agarwal, Rajni ; Harris, Richard E. ; Feig, Stephen A. ; Territo, Mary C. ; Collins, Robert H. ; McSweeney, Peter A. ; Copelan, Edward A. ; Khan, Shakila P. ; Woolfrey, Ann ; Storer, Barry. / Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. In: Blood. 2006 ; Vol. 108, No. 5. pp. 1485-1491.
@article{5965124083a94b05ad52d59672baacb1,
title = "Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy",
abstract = "In 87 patients with aplastic anemia who failed to respond to immunosuppressive treatment, we determined the minimal dose of total body irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclophosphamide (CY, 50 mg/kg x 4) to achieve engraftment of unrelated donor marrow. TBI was started at 3 x 200 cGy, to be escalated or deescalated in steps of 200 cGy depending on graft failure or toxicity. Patients were aged 1.3 to 53.5 years (median, 18.6 years). The interval from diagnosis to transplantation was 3 to 328 months (median, 14.6 months). Donors were HLA-A, -B, -C, -DR, and -DQ identical for 62 patients, and nonidentical for 1 to 3 HLA loci at the antigen or allele level for 25. The dose-limiting toxicity was diffuse pulmonary injury. The optimum TBI dose was 1 x 200 cGy. Nine patients did not tolerate ATG and were prepared with CY + TBI. Graft failure occurred in 5{\%} of patients. With a median follow-up of 7 years, 38 (61{\%}) of 62 HLA-identical, and 10 (40{\%}) of 25 HLA-nonidentical transplant recipients are surviving. The highest survival rate with HLA-identical transplants was observed at 200 cGy TBI. Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions.",
author = "Deeg, {H. Joachim} and Margaret O'Donnell and Jakub Tolar and Rajni Agarwal and Harris, {Richard E.} and Feig, {Stephen A.} and Territo, {Mary C.} and Collins, {Robert H.} and McSweeney, {Peter A.} and Copelan, {Edward A.} and Khan, {Shakila P.} and Ann Woolfrey and Barry Storer",
year = "2006",
month = "9",
day = "1",
doi = "10.1182/blood-2006-03-005041",
language = "English (US)",
volume = "108",
pages = "1485--1491",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy

AU - Deeg, H. Joachim

AU - O'Donnell, Margaret

AU - Tolar, Jakub

AU - Agarwal, Rajni

AU - Harris, Richard E.

AU - Feig, Stephen A.

AU - Territo, Mary C.

AU - Collins, Robert H.

AU - McSweeney, Peter A.

AU - Copelan, Edward A.

AU - Khan, Shakila P.

AU - Woolfrey, Ann

AU - Storer, Barry

PY - 2006/9/1

Y1 - 2006/9/1

N2 - In 87 patients with aplastic anemia who failed to respond to immunosuppressive treatment, we determined the minimal dose of total body irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclophosphamide (CY, 50 mg/kg x 4) to achieve engraftment of unrelated donor marrow. TBI was started at 3 x 200 cGy, to be escalated or deescalated in steps of 200 cGy depending on graft failure or toxicity. Patients were aged 1.3 to 53.5 years (median, 18.6 years). The interval from diagnosis to transplantation was 3 to 328 months (median, 14.6 months). Donors were HLA-A, -B, -C, -DR, and -DQ identical for 62 patients, and nonidentical for 1 to 3 HLA loci at the antigen or allele level for 25. The dose-limiting toxicity was diffuse pulmonary injury. The optimum TBI dose was 1 x 200 cGy. Nine patients did not tolerate ATG and were prepared with CY + TBI. Graft failure occurred in 5% of patients. With a median follow-up of 7 years, 38 (61%) of 62 HLA-identical, and 10 (40%) of 25 HLA-nonidentical transplant recipients are surviving. The highest survival rate with HLA-identical transplants was observed at 200 cGy TBI. Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions.

AB - In 87 patients with aplastic anemia who failed to respond to immunosuppressive treatment, we determined the minimal dose of total body irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclophosphamide (CY, 50 mg/kg x 4) to achieve engraftment of unrelated donor marrow. TBI was started at 3 x 200 cGy, to be escalated or deescalated in steps of 200 cGy depending on graft failure or toxicity. Patients were aged 1.3 to 53.5 years (median, 18.6 years). The interval from diagnosis to transplantation was 3 to 328 months (median, 14.6 months). Donors were HLA-A, -B, -C, -DR, and -DQ identical for 62 patients, and nonidentical for 1 to 3 HLA loci at the antigen or allele level for 25. The dose-limiting toxicity was diffuse pulmonary injury. The optimum TBI dose was 1 x 200 cGy. Nine patients did not tolerate ATG and were prepared with CY + TBI. Graft failure occurred in 5% of patients. With a median follow-up of 7 years, 38 (61%) of 62 HLA-identical, and 10 (40%) of 25 HLA-nonidentical transplant recipients are surviving. The highest survival rate with HLA-identical transplants was observed at 200 cGy TBI. Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions.

UR - http://www.scopus.com/inward/record.url?scp=33748157848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748157848&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-03-005041

DO - 10.1182/blood-2006-03-005041

M3 - Article

C2 - 16684959

AN - SCOPUS:33748157848

VL - 108

SP - 1485

EP - 1491

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -